Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors
CEO Ken Frazier had to argue the case that Merck has a diversified portfolio in yet another strong quarter for the PD-1 inhibitor Keytruda.
You may also be interested in...
Keytruda Rules The Roost, But Merck & Co. Highlights Progress In Other Areas
Merck & Co. outlined its near-term growth drivers during an investor day, including Keytruda in breast and prostate cancer, as well as vaccines for RSV and CMV, a drug for chronic cough and a long-acting HIV medicine.
Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio
Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.
LifeArc CEO: UK Charity Is Cashing In Its Keytruda ‘Jackpot’ To Expand R&D Focus
The CEO of LifeArc tells Scrip why the UK-based medical research charity has decided to monetize a part of its royalty interest in Merck’s hugely successful cancer drug, Keytruda.